Compare KEQU & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | ATOS |
|---|---|---|
| Founded | 1906 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.6M | 100.8M |
| IPO Year | N/A | 2012 |
| Metric | KEQU | ATOS |
|---|---|---|
| Price | $39.07 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 9.3K | ★ 911.6K |
| Earning Date | 12-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.94 | N/A |
| Revenue | ★ $285,515,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.59 | ★ N/A |
| Revenue Growth | ★ 43.02 | N/A |
| 52 Week Low | $30.33 | $0.55 |
| 52 Week High | $71.33 | $1.29 |
| Indicator | KEQU | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 41.74 |
| Support Level | $37.50 | $0.68 |
| Resistance Level | $41.04 | $0.99 |
| Average True Range (ATR) | 1.44 | 0.05 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 51.45 | 14.09 |
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.